KR102719065B1 - Cd38 조정 항체 - Google Patents

Cd38 조정 항체 Download PDF

Info

Publication number
KR102719065B1
KR102719065B1 KR1020207000253A KR20207000253A KR102719065B1 KR 102719065 B1 KR102719065 B1 KR 102719065B1 KR 1020207000253 A KR1020207000253 A KR 1020207000253A KR 20207000253 A KR20207000253 A KR 20207000253A KR 102719065 B1 KR102719065 B1 KR 102719065B1
Authority
KR
South Korea
Prior art keywords
antibody
sequence
seq
antigen
acd38
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207000253A
Other languages
English (en)
Korean (ko)
Other versions
KR20200021069A (ko
Inventor
파스칼 머치어스
앤 구비어
케빈 모울더
니나 아이슬러
조세핀 살리무
시몬 플로스토
비트리즈 고예네체아 코르조
헤만타 바루아
비안카 프린즈
Original Assignee
블랙 벨트 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블랙 벨트 테라퓨틱스 리미티드 filed Critical 블랙 벨트 테라퓨틱스 리미티드
Publication of KR20200021069A publication Critical patent/KR20200021069A/ko
Application granted granted Critical
Publication of KR102719065B1 publication Critical patent/KR102719065B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020207000253A 2017-06-08 2018-06-08 Cd38 조정 항체 Active KR102719065B1 (ko)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201762517149P 2017-06-08 2017-06-08
US201762517150P 2017-06-08 2017-06-08
US62/517,150 2017-06-08
US62/517,149 2017-06-08
US201762517165P 2017-06-09 2017-06-09
US201762517753P 2017-06-09 2017-06-09
US201762517745P 2017-06-09 2017-06-09
US201762517740P 2017-06-09 2017-06-09
US201762517734P 2017-06-09 2017-06-09
US201762517164P 2017-06-09 2017-06-09
US62/517,164 2017-06-09
US62/517,740 2017-06-09
US62/517,734 2017-06-09
US62/517,165 2017-06-09
US62/517,753 2017-06-09
US62/517,745 2017-06-09
US201762582676P 2017-11-07 2017-11-07
US201762582666P 2017-11-07 2017-11-07
US201762582653P 2017-11-07 2017-11-07
US201762582681P 2017-11-07 2017-11-07
US62/582,676 2017-11-07
US62/582,681 2017-11-07
US62/582,666 2017-11-07
US62/582,653 2017-11-07
PCT/EP2018/065243 WO2018224685A1 (en) 2017-06-08 2018-06-08 Cd38 modulating antibody

Publications (2)

Publication Number Publication Date
KR20200021069A KR20200021069A (ko) 2020-02-27
KR102719065B1 true KR102719065B1 (ko) 2024-10-17

Family

ID=62620847

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207000253A Active KR102719065B1 (ko) 2017-06-08 2018-06-08 Cd38 조정 항체
KR1020257004706A Pending KR20250025514A (ko) 2017-06-08 2018-06-08 Cd38 조정 항체
KR1020207000247A Active KR102770106B1 (ko) 2017-06-08 2018-06-08 Cd38 조정 항체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257004706A Pending KR20250025514A (ko) 2017-06-08 2018-06-08 Cd38 조정 항체
KR1020207000247A Active KR102770106B1 (ko) 2017-06-08 2018-06-08 Cd38 조정 항체

Country Status (8)

Country Link
US (3) US12343394B2 (2)
EP (2) EP3635002A1 (2)
JP (3) JP7237951B2 (2)
KR (3) KR102719065B1 (2)
CN (2) CN110997722B (2)
AU (3) AU2018280871B2 (2)
CA (2) CA3066553A1 (2)
WO (2) WO2018224685A1 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102719065B1 (ko) 2017-06-08 2024-10-17 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
SG11202000321PA (en) 2017-08-16 2020-02-27 Black Belt Therapeutics Ltd Cd38 modulating antibody
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer
CN113614107A (zh) * 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
US12310965B2 (en) 2019-03-29 2025-05-27 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
JP7555953B2 (ja) * 2019-03-29 2024-09-25 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ３８に結合する操作されたバリアント抗体
US12181485B2 (en) 2020-09-10 2024-12-31 CASI Pharmaceuticals, Inc Methods of blood screening
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
AU2011202520C1 (en) 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
DK2511297T3 (en) 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies and their applications
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
AU2016228249A1 (en) 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
KR101552735B1 (ko) * 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
KR20090088946A (ko) 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2009301580B2 (en) 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2970471A2 (en) 2013-03-15 2016-01-20 F. Hoffmann-La Roche AG Anti-crth2 antibodies and their use
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
WO2016089862A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
ES2927119T3 (es) 2015-04-08 2022-11-02 Sorrento Therapeutics Inc Productos terapéuticos de anticuerpos que se unen a CD38
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
KR102719065B1 (ko) 2017-06-08 2024-10-17 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
US12590171B2 (en) * 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof

Also Published As

Publication number Publication date
KR20200021069A (ko) 2020-02-27
JP2020522281A (ja) 2020-07-30
US12343394B2 (en) 2025-07-01
CA3066555A1 (en) 2018-12-13
US20230103584A1 (en) 2023-04-06
JP7237951B2 (ja) 2023-03-13
AU2018280869B2 (en) 2025-01-02
CN110997723A (zh) 2020-04-10
NZ760448A (en) 2025-03-28
KR102770106B1 (ko) 2025-02-21
CN110997723B (zh) 2023-09-26
US20250367286A1 (en) 2025-12-04
CA3066553A1 (en) 2018-12-13
EP3635002A1 (en) 2020-04-15
WO2018224685A1 (en) 2018-12-13
JP7237950B2 (ja) 2023-03-13
NZ760342A (en) 2025-03-28
US20210277138A1 (en) 2021-09-09
AU2025201908A1 (en) 2025-04-03
EP3635003A1 (en) 2020-04-15
KR20200021068A (ko) 2020-02-27
AU2018280871A1 (en) 2020-01-16
KR20250025514A (ko) 2025-02-21
JP7467584B2 (ja) 2024-04-15
CN110997722B (zh) 2023-09-26
AU2018280869A1 (en) 2020-01-16
AU2018280871B2 (en) 2024-09-26
AU2018280871A8 (en) 2020-01-30
CN110997722A (zh) 2020-04-10
JP2020522280A (ja) 2020-07-30
US12161717B2 (en) 2024-12-10
JP2023030071A (ja) 2023-03-07
WO2018224683A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
KR102719065B1 (ko) Cd38 조정 항체
JP7596447B2 (ja) Ｃｄ３８調節抗体
KR102770110B1 (ko) Cd38 항체
US12304964B2 (en) CD38 modulating antibody
US11542338B2 (en) CD38 modulating antibody
KR102770104B1 (ko) Cd38 조정 항체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200103

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210607

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240213

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240927

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241014

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241014

End annual number: 3

Start annual number: 1

PG1601 Publication of registration